These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3950060)

  • 1. Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.
    Williams PJ; Hull JH; Sarubbi FA; Rogers JF; Wargin WA
    J Clin Pharmacol; 1986 Feb; 26(2):79-86. PubMed ID: 3950060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of amikacin pharmacokinetic/pharmacodynamic index on treatment response in critically ill patients.
    Ruiz J; Ramirez P; Company MJ; Gordon M; Villarreal E; Concha P; Aroca M; Frasquet J; Remedios-Marqués M; Castellanos-Ortega Á
    J Glob Antimicrob Resist; 2018 Mar; 12():90-95. PubMed ID: 29017888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, randomized study of amikacin and gentamicin in serious infections with focus on efficacy, toxicity and duration of serum levels above the MIC.
    Holm SE; Hill B; Löwestad A; Maller R; Vikerfors T
    J Antimicrob Chemother; 1983 Oct; 12(4):393-402. PubMed ID: 6643334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrotoxicity induced by gentamicin and amikacin.
    Smith CR; Maxwell RR; Edwards CQ; Rogers JF; Lietman PS
    Johns Hopkins Med J; 1978 Mar; 142(3):85-90. PubMed ID: 342789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tobramycin and amikacin nephrotoxicity. Value of serum creatinine versus urinary concentration of beta-2-microglobulin.
    Gatell JM; SanMiguel JG; Zamora L; Araujo V; Castells C; Moreno A; Jimenez de Anta MT; Marin JL; Elena M; Ballesta A
    Nephron; 1985; 41(4):337-43. PubMed ID: 3906418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminoglycoside dosages and nephrotoxicity: quantitative relationships.
    Rougier F; Ducher M; Maurin M; Corvaisier S; Claude D; Jelliffe R; Maire P
    Clin Pharmacokinet; 2003; 42(5):493-500. PubMed ID: 12739987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin.
    Lerner SA; Schmitt BA; Seligsohn R; Matz GJ
    Am J Med; 1986 Jun; 80(6B):98-104. PubMed ID: 3524221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function.
    Sweileh WM
    Fundam Clin Pharmacol; 2009 Aug; 23(4):515-20. PubMed ID: 19709328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amikacin therapy for gram-negative septicemia.
    Meyer RD; Lewis RP; Finegold SM
    Am J Med; 1977 Jun; 62(6):930-5. PubMed ID: 868908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled study of the nephrotoxicity of mezlocillin and amikacin in the neonate.
    Adelman RD; Wirth F; Rubio T
    Am J Dis Child; 1987 Nov; 141(11):1175-8. PubMed ID: 3314475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides.
    Raveh D; Kopyt M; Hite Y; Rudensky B; Sonnenblick M; Yinnon AM
    QJM; 2002 May; 95(5):291-7. PubMed ID: 11978900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminoglycoside-related nephrotoxicity in the premature newborn.
    Rajchgot P; Prober CG; Soldin S; Perlman M; Good F; Harding E; Klein J; MacLeod S
    Clin Pharmacol Ther; 1984 Mar; 35(3):394-401. PubMed ID: 6365403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Therapeutic Drug Monitoring on Once-Daily Regimen of Amikacin in Patients With Urinary Tract Infection: A Prospective Observational Study.
    Jayakumar I; Mathaiyan J; Mandal J; Deepanjali S; Sreenivasan SK
    Ther Drug Monit; 2020 Dec; 42(6):841-847. PubMed ID: 32947556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aminoglycoside dosing in renal transplant patients. Comparison of nomogram and individualized pharmacokinetic methods in patients with shifting renal function.
    Tofte RW; Canafax DM; Simmons RL; Peterson PK
    Ann Surg; 1982 Mar; 195(3):287-93. PubMed ID: 7036923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.
    van Altena R; Dijkstra JA; van der Meer ME; Borjas Howard JF; Kosterink JG; van Soolingen D; van der Werf TS; Alffenaar JW
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis.
    de Jager P; van Altena R
    Int J Tuberc Lung Dis; 2002 Jul; 6(7):622-7. PubMed ID: 12102302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 'high-dose' amikacin in children.
    Kumor KM; McDonald JM; Lietman PS
    Dev Pharmacol Ther; 1984; 7(6):368-76. PubMed ID: 6518944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin.
    Gatell JM; San Miguel JG; Zamora L; Araujo V; Bonet M; Bohé M; Jimenez de Anta MT; Farré M; Elena M; Ballesta A; Marin JL
    Antimicrob Agents Chemother; 1983 Jun; 23(6):897-901. PubMed ID: 6614894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low serum albumin and the increased risk of amikacin nephrotoxicity.
    Contreras AM; Ramírez M; Cueva L; Alvarez S; de Loza R; Gamba G
    Rev Invest Clin; 1994; 46(1):37-43. PubMed ID: 8079062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentrations and inhibitory ratios during amikacin therapy of gram-negative infections.
    Farchione LA; Chudzik GM
    J Clin Pharmacol; 1978; 18(8-9):432-8. PubMed ID: 690253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.